AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01646255
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period
Trial: NCT00461006
Drug: Actos
RxNorm normalized name: Actos
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45mg po daily
Trial: NCT00461006
Drug: aleglitazar
RxNorm normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6mg po daily
Trial: NCT01646255
Drug: L-dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
Trial: NCT02041260
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02596620
Drug: Nexium
RxNorm normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
Trial: NCT02596620
Drug: Amolin
RxNorm normalized name: Ethamolin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
Trial: NCT01043172
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
Trial: NCT00112736
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00112736
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04638036
Drug: Cetuximab-IRDye800
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous administration of a pre-dose of 75 mg unlabeled Cetuximab followed by 15 mg Cetuximab-IRDye800 prior to the study procedures
Trial: NCT01243203
Drug: Champix
RxNorm normalized name: chloroxylenol
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
Trial: NCT02685449
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Trial: NCT02685449
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Trial: NCT02685449
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Trial: NCT01000480
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
Trial: NCT01000480
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
Trial: NCT01919450
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Trial: NCT00939510
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
Trial: NCT02596620
Drug: Cravit
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
Trial: NCT02596620
Drug: Flagyl
RxNorm normalized name: Flagyl
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
Trial: NCT00000491
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004172
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004172
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004172
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00093015
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
Trial: NCT00829634
Drug: l-methamphetamine
RxNorm normalized name: L-methamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg of l-methamphetamine per day throughout the 2 week study
Trial: NCT00829634
Drug: d-methamphetamine
RxNorm normalized name: D-methamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
Trial: NCT00742391
Drug: PEP005 (ingenol mebutate) Gel
RxNorm normalized name: Ingenol Mebutate Topical Gel
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two day treatment
Trial: NCT01758640
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose warfarin of 5mg or less per day
Trial: NCT01758640
Drug: phenindione
RxNorm normalized name: phenindione
DrugBank: Phenindione (DB00498)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenindione of 100mg or less per day
Trial: NCT02871570
Drug: Rivipansel
RxNorm normalized name: Rivipansel
DrugBank: Rivipansel (DB12778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of IV Rivipansel over 20 minutes
Trial: NCT01220596
Drug: Entecavir and Pegylated interferon α-2a Sequential Treatment Group
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
Trial: NCT01220596
Drug: Pegylated interferon α-2a Monotreatment Group
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
Trial: NCT02652572
Drug: Granexin
RxNorm normalized name: GRANEXIN
DrugBank: ACT-1 peptide (DB18201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Trial: NCT03279861
Drug: Entresto
RxNorm normalized name: Entresto
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First line therapy in Entresto arm
Trial: NCT03279861
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First line therapy in usual meds arm
Trial: NCT00739739
Drug: PD 0299685 at 15mg BID
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
Trial: NCT00739739
Drug: PD 0299685 at 30mg BID
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
Trial: NCT00739739
Drug: placebo for PD 0299685
RxNorm normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
Trial: NCT01582646
Drug: Terbutaline sustained release 5 mg
RxNorm normalized name: terbutaline Extended Release Oral Tablet
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
Trial: NCT03830086
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
Trial: NCT03830086
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
Trial: NCT03830086
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
Trial: NCT03830086
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
Trial: NCT03830086
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
Trial: NCT01947790
Drug: pioglitazone group
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01947790
Drug: Metformin group
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02931175
Drug: ACTH gel
RxNorm normalized name: ACTH Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
Trial: NCT03290846
Drug: Secretin Human
RxNorm normalized name: Secretin human
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized, single-blinded secretin hydrochloride infusion.
Trial: NCT04431375
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir \[antiviral\] 300mg PO once a day .
Trial: NCT03290846
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized, single-blinded saline infusion.
Trial: NCT00515905
Drug: Sevoflurane/propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane/propofol
Trial: NCT03174184
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of rifampin at a dosage of 20 mg/kg daily
Trial: NCT03174184
Drug: MEROPENEM 2 grams TID
RxNorm normalized name: meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration at a dosage of 2 grams thrice daily
Trial: NCT03174184
Drug: MEROPENEM 1 gram TID
RxNorm normalized name: meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration at a dosage of 1 gram thrice daily
Trial: NCT03174184
Drug: MEROPENEM 3 grams QD
RxNorm normalized name: meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration at a dosage of 3 grams once daily
Trial: NCT03174184
Drug: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
RxNorm normalized name: Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
Trial: NCT03174184
Drug: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
RxNorm normalized name: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
Trial: NCT00973752
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
Trial: NCT00973752
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
Trial: NCT00174382
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
Trial: NCT00973752
Drug: PEG-asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
Trial: NCT00973752
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecally during Induction and CNS therapy
Trial: NCT00973752
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
Trial: NCT00973752
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenously during Consolidation 1 Therapy
Trial: NCT02655263
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Somatropin infusion (Genotropin®)
Trial: NCT00192712
Drug: irinotecan, gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00703781
Drug: bromfenac ophthalmic solution
RxNorm normalized name: bromfenac Ophthalmic Solution
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sterile ophthalmic solution
Trial: NCT01510977
Drug: polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after first colonoscopy failure, polyethylene glycol 2L addition
Trial: NCT01969708
Drug: aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01969708
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01118884
Drug: Promethazine
RxNorm normalized name: Promethazine
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
Trial: NCT03446625
Drug: Resveratrol
RxNorm normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Trial: NCT00125645
Drug: Irbesartan Oral Tablet
RxNorm normalized name: irbesartan Oral Tablet
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01079065
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03040141
Drug: Low dose of VIS410
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
Trial: NCT03040141
Drug: High dose of VIS410
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
Trial: NCT04345341
Drug: TAP block with liposomal bupivacaine and bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injecting the mixture of bupivacaine with liposomal bupivacaine in transversus abdominis plane to block the somatic nerves
Trial: NCT01723735
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Trial: NCT01723735
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: overencapsulated tablet~Route of administration: oral
Trial: NCT01723735
Drug: Ezetimibe Placebo
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT01723735
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT00000547
Drug: enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00073658
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01195883
Drug: Crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
Trial: NCT00073658
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01195883
Drug: Colloid
RxNorm normalized name: tin colloid
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
Trial: NCT02355665
Drug: Nicotine Spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Spray
Trial: NCT01833923
Drug: anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral medicine.
Trial: NCT00525512
Drug: tiotropium 18 mcg
RxNorm normalized name: tiotropium 18 MCG Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation once daily of 18mcg tiotropium via handihaler
Trial: NCT01471145
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
Trial: NCT00939094
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, once daily
Trial: NCT01863459
Drug: Lisdexamfetamine Dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes